DONATE TODAY
To Increase Patient Access
The TRIDENT study is intended for patients 
recently diagnosed with glioblastoma
multiforme (GBM)..
The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from the Optune® System together with radiation therapy and temozolomide in newly diagnosed glioblastoma (GBM) patients.

Patients in the study will use Optune® as well as the other standard of care treatments for GBM. The trial is expected to enroll 950 patients. Enrollment is open in multiple centers in the US, Canada, Japan, and across Europe.

Tumor Treating Fields (TTFields)

Tumor Treating Fields (TTFields) are low-intensity wave-like electric fields, tuned to interfere with the division process of cancer cells.

TTFields are delivered to the region of the tumor using the Optune® medical device. The Optune® System is a portable, light-weight, battery operated device designed to deliver TTFields to glioblastoma (GBM) tumors.

Patients receiving TTFields need to wear four adhesive patches called “transducer arrays” on their scalp, which deliver the fields non-invasively to the location of the GBM tumor. The system is intended for continuous use by patients.
TTFields have been approved by the FDA for treatment of adult patients with recurrent and newly diagnosed GBM. What makes the TRIDENT study different is that is testing the use of Optune® together with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed patients.
VISIT NOVOCURE FOR MORE DETAILS

Study Overview

The TRIDENT study is for patients recently diagnosed with glioblastoma (GBM). This clinical trial is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the Optune® treatment paired with radiation therapy and temozolomide in newly diagnosed GBM patients [About TTFields].  All patients participating in this study will receive Optune® treatment [The TRIDENT Trial].

Please visit the Novocure Trident Trial site for more details. 
If you want to take part in the TRIDENT trial, please contact one of the participating centers [TRIDENT Centers] as soon as possible. Consult your treating physician if you have questions about your medical condition and if a clinical trial is right for you.
An updated list of medical centers participating in TRIDENT is also accessible on clinicaltrials.gov. If you are unable to reach a study center, please email clinicaltrials@novocure.com or Trident@novocure.com with questions, placing “TRIDENT Questions” in the subject line.
FIND A NOVOCURE TRIAL

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.
DONATE
envelopephone linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram